Intercept Pharmaceuticals

Health Care  |  Biotechnology
17.84 -0.98 -5.21%
Stock Price | May 18, 2022, 2:41 p.m.
Bid: 17.81
Ask: 17.87
Prev. Close: 18.82
52 Week Low: 11.6
52 Week High: 22.36
PE Ratio:
Dividend Yield: %

Company Summary

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Read more Read less

Recently Viewed Tickers

6 years ago
6 years ago
6 years ago
6 years ago

Free 5 Biotech Stocks On Deck With The FDA

6 years ago
6 years ago

Premium 05/15/2015 Recap - Members only

7 years ago

Free Intercept Pharmaceuticals Breaks Out

7 years ago